OCT 09, 2019 6:00 AM PDT

Multilevel Interventions in Cancer Prevention and Control: A Community-Based Translational Research Framework to Address Prostate Cancer Disparities

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director of the Cancer Health Equity Institute Morehouse School of Medicine (MSM)
    Biography
      Dr. Rivers is the Director of the Cancer Health Equity Institute at Morehouse School of Medicine (MSM). Dr. Rivers is nationally and internationally recognized as a leader in cancer disparities research and currently serves as a member of the National Institutes of Health (NIH) National Advisory Council on Minority Health and Health Disparities (NACMHD). Dr. Rivers is an active member in the American Association for Cancer Research (AACR) community and regularly serves on the faculty for the Scientist to Survivor program. More recently, Dr. Rivers was elected to serve as Chairperson for the Minorities in Cancer Research Council of the AACR. Dr. Rivers is a behavioral scientist with a broad background in implementation science and public health, with specific training and expertise in health behavior research methodologies for addressing health disparities, such as the lay health model and Community-based Participatory Research framework. Dr. Rivers' specific program of research is focused on addressing prostate cancer disparities among African Americans and exploring the role of novel communication interventions, such as mobile health technology. Currently, Dr. Rivers is leading several large randomized controlled trials, funded by NIH and NIMHD R01, to evaluate and characterize app usage and acceptability for education and care coordination among African American men diagnosed with prostate cancer. Dr. Rivers is Multiple-Principal Investigator for the NIH NCI funded U54 Cancer Research Partnership between MSM, Tuskegee University, and the University of Alabama-Birmingham Comprehensive Cancer Center (UAB CCC). Dr. Rivers also directs the Integrating Special Populations Program of the NIH NCATS funded Georgia Clinical and Translational Science Alliance.

    Abstract

    Introduction: Despite the current declines in prostate cancer mortality, African Americans (AA) continue to experience a 60% higher incidence and are twice as likely to die in comparison to men of other racial and ethnic groups. A host of factors have been postulated to explain this inequity, including access to care, patient-centered communication, concordance of patient and physician race, level of prostate cancer knowledge, attitudes and perceptions of care, socioeconomic differences, differences in biological manifestation, type and aggressiveness of treatment, diet, genetics, and lifestyle and environmental factors.  There has been no consistent strategy employed to address prostate cancer disparities, not withstanding an increased effort to provide prostate cancer screening.  Screening and early detection are likely to assist; however, the scientific evidence to date has been insufficient to definitively conclude screening for prostate cancer reduces deaths.  While the uncertainty of the effectiveness of the screening modalities for prostate cancer persists, patients are encouraged to participate in the informed decision making (IDM) process with their healthcare provider to effectively incorporate their values and preferences. However, the extent of the patient-provider interaction in general has been found to be a barrier to securing adequate healthcare among racial and ethnic groups.  Mistrust, fear, discrimination, and racism have all been cited as factors of concern, for African American men in particular, when interfacing with the healthcare system. Four patient mediating outcomes of IDM include: 1) individual risk assessment, 2) consideration of values and beliefs, 3) knowledge of the risk and benefits of screening, and 4) consideration of age and lifespan issues (i.e., existing co-morbidities).  The extent of IDM in clinical settings is unclear.  The goal of this study was to establish effective delivery practice strategies with current recommendations for IDM for prostate cancer screening among African American men.  The use of Community Navigation and digital technology in community based settings allow for the innovativeness of this study.  We conducted a community-based, Randomized Controlled Trial, to assess the effectiveness of community based education as compared to clinical setting usual care in the delivery of the IDM process. The design of the study allowed for the evaluation of the effectiveness of utilizing the Community Navigators and an enhanced Patient Decision Aid in community-based venues to disseminate IDM to AA men. The two study arms were: 1) control (usual care group) and 2) experimental (enhanced patient decision aide and lay health advisory). The eligibility criteria for the participants included: 1) have not been diagnosed or treated for any type of cancer, 2) self-identify as AA, 3) able to understand English (ability to repeat back in their own words), 4) in the age range 40-70, and 5) working telephone number.  Study findings will be presented related to the primary outcome, IDM, measured through four domains: Knowledge, Decisional Conflict, Control Preferences, and Decisional Self-Efficacy. The findings of this study have informed effective community-based strategies with current recommendations for IDM.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    OCT 09, 2019 6:00 AM PDT

    Multilevel Interventions in Cancer Prevention and Control: A Community-Based Translational Research Framework to Address Prostate Cancer Disparities

    C.E. Credits: P.A.C.E. CE Florida CE

    Specialty

    Animal Research

    Cell Biology

    Molecular Biology

    Immunology

    Brain

    Cancer Research

    Molecular Diagnostics

    Medicine

    Cancer Therapeutics

    Immune System

    Animal Behavior

    Chemistry

    Genomics

    Gene Sequencing

    Systems Biology

    Geography

    North America75%

    Asia25%

    Registration Source

    Website Visitors100%

    Job Title

    Educator/Faculty50%

    Biologist50%

    Organization

    Academic Institution50%

    Research Institute25%

    Hospital25%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more